RxDoctor Payments Data

Susan Ban, MD

Internal Medicine · Tustin, CANPI 1053324970

Payments from drug & device makers

$1,727in general payments, 2019–2025

Across 93 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$317
  • Pfizer$238
  • AstraZeneca$198
  • Lilly USA, LLC$188
  • Amgen$171
  • Merck$127
  • plus $488 from 16 others

What the payments were for

  • Food & beverage$1,727100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,727 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$202,965
Medicare patients
263
Services billed
2,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$60,761
JardianceEmpagliflozin42$59,361
FarxigaDapagliflozin Propanediol16$24,343
TrulicityDulaglutide14$18,536
JanuviaSitagliptin Phosphate12$17,161
MyrbetriqMirabegron22$14,315
MounjaroTirzepatide13$13,427
OzempicSemaglutide11$10,129
Breo ElliptaFluticasone/Vilanterol15$9,146
Spiriva RespimatTiotropium Bromide12$8,020
SynthroidLevothyroxine Sodium70$7,262
Dexlansoprazole DrDexlansoprazole14$5,254
Rosuvastatin Calcium292$5,207
PaxlovidNirmatrelvir/Ritonavir41$4,288
Atorvastatin Calcium481$4,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$317$67,38154 claims
PfizerEliquis, Paxlovid$238$65,04998 claims
Lilly USA, LLCTrulicity, Mounjaro$188$31,96327 claims
AstraZenecaFarxiga$198$24,34316 claims
MerckJanuvia$127$17,16112 claims
Novo NordiskOzempic$20$10,12911 claims
GSKBreo Ellipta$18$9,14615 claims
AbbVieSynthroid$39$7,26270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Tustin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →